-INCLUSION CRITERIA:

          1. Subjects with cytologically or histologically confirmed locally advanced or metastatic
             small bowel or colorectal adenocarcinoma

          2. Subjects must have received two prior lines of systemic therapy unless the subject is
             not eligible to receive standard therapy or declines standard treatment

          3. Subjects must have measurable disease

          4. ECOG performance status <= 2

          5. Adequate hematologic function at screening, as follows:

               -  Absolute neutrophil count (ANC) >=1 x 10^9/L

               -  Hemoglobin >= 9 g/dL

               -  Platelets >= 75,000/microliter

          6. Adequate renal and hepatic function at screening, as follows:

             - Serum creatinine <= 1.5 x upper limit of normal (ULN) OR

             Measured or calculated creatinine clearance >= 40 mL/min for participant with
             creatinine levels > 1.5 X institutional ULN (GFR can also be used in place of
             creatinine or CrCl);

               -  Bilirubin <= 1.5 x ULN OR in subjects with Gilbert s syndrome, a total bilirubin
                  <= 3.0 x ULN

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 2.5 x ULN,
                  unless liver metastases are present, then values must be <= 3 x ULN)

          7. The effects of the immunotherapies on the developing human fetus are unknown; thus,
             women of childbearing potential and men must agree to use highly effective
             contraception (hormonal or barrier method of birth control; abstinence) prior to study
             entry, for the duration of study treatment and up to two months after the last dose of
             study drug. Should a woman become pregnant or suspect she is pregnant while she or her
             partner is participating in this study, she should inform her treating physician
             immediately.

          8. Participants serologically positive for HIV, Hep B, Hep C are eligible as long as the
             viral loads are undetectable by quantitative PCR. HIV positive participants must have
             CD4 count >= 200 cells per cubic millimeter at enrollment, be on stable antiretroviral
             therapy for at least 4 weeks and have no reported opportunistic infections or
             Castleman s disease within 12 months prior to enrollment.

          9. Ability of subject to understand and the willingness to sign a written informed
             consent document.

        EXCLUSION CRITERIA:

          1. Participants with prior investigational drug, chemotherapy, immunotherapy or any prior
             radiotherapy (except for palliative bone directed therapy) within the past 28 days
             prior to the first drug administration except if the investigator has assessed that
             all residual treatment-related toxicities have resolved or are minimal and feel the
             participant is otherwise suitable for enrollment. Additionally, current therapies
             (e.g., maintenance capecitabine) may be continued where in the opinion of the
             investigator stopping such therapies may increase the risk of disease progression.
             Also, participants may continue adjuvant hormonal therapy in the setting of a
             definitively treated cancer (e.g. breast).

          2. Participants with microsatellite unstable or mismatch repair deficient disease.

          3. Major surgery within 28 days prior to the first drug administration (minimally
             invasive procedures such as diagnostic biopsies are permitted).

          4. Known life-threatening side effects resulting from prior checkpoint inhibitor therapy
             (e.g., colitis, pneumonitis, fulminant hepatitis which led to permanent
             discontinuation of prior checkpoint therapy). Autoimmune toxicity which was not life
             threatening (e.g., arthritis) or did not lead to discontinuation of prior checkpoint
             therapy is allowed.

          5. Known active brain or central nervous system metastasis (less than a month out from
             definitive radiotherapy or surgery), seizures requiring anticonvulsant treatment (<3
             months) or clinically significant cerebrovascular accident (<3 months). In order to be
             eligible participants must have repeat CNS imaging at least a month after definitive
             treatment showing stable CNS disease. Participants with evidence of intratumoral or
             peritumoral hemorrhage on baseline imaging are also excluded unless the hemorrhage is
             grade <= 1 and has been shown to be stable on two consecutive imaging scans.

          6. Pregnant women are excluded from this study because these drugs have not been tested
             in pregnant women and there is potential for teratogenic or abortifacient effects.
             Because there is an unknown but potential risk for adverse events in nursing infants
             secondary to treatment of the mother with these immunotherapies, breastfeeding should
             be discontinued if the mother is treated on this protocol.

          7. Active autoimmune disease that might deteriorate when receiving an immunostimulatory
             agent with exception of:

               -  Diabetes type I, eczema, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid
                  disease or other mild autoimmune disorders not requiring immunosuppressive
                  treatment;

               -  Subjects requiring hormone replacement with corticosteroids are eligible if the
                  steroids are administered only for the purpose of hormonal replacement and at
                  doses <= 10 mg of prednisone or equivalent per day;

               -  Administration of steroids for other conditions through a route known to result
                  in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation)
                  is acceptable;

               -  Subjects on systemic intravenous or oral corticosteroid therapy with the
                  exception of physiologic doses of corticosteroids (<= the equivalent of
                  prednisone 10 mg/day) or other immunosuppressive agents such as azathioprine or
                  cyclosporin A are excluded on the basis of potential immune suppression. For
                  these subjects these excluded treatments must be discontinued at least 1 weeks
                  prior to enrollment for recent short course use (<= 14 days) or discontinued at
                  least 4 weeks prior to enrollment for long term use (> 14 days). In addition, the
                  use of corticosteroids as premedication for contrast-enhanced studies is allowed
                  prior to enrollment and on study.

          8. Subjects with a history of serious intercurrent chronic or acute illness, such as
             cardiac or pulmonary disease, hepatic disease, bleeding diathesis or recent (within 3
             months) clinically significant bleeding events or other illness considered by the
             Investigator as high risk for investigational drug treatment.

          9. Subjects unwilling to accept blood products as medically indicated.

         10. History of second malignancy within 3 years of enrollment except for the following:
             adequately treated localized skin cancer, cervical carcinoma in situ, superficial
             bladder cancer, or other localized malignancy which has been adequately treated or
             malignancy which does not require active systemic treatment (e.g., low risk CLL).

         11. Subjects with a known severe hypersensitivity reaction to a monoclonal antibody (grade
             >= 3 NCI-CTCAE v5) will be evaluated by the allergy/immunology team prior to
             enrollment.

         12. Receipt of any organ transplantation requiring ongoing immunosuppression.

         13. Receipt of prior lymphodepleting chemotherapy (e.g. cyclophosphamide or fludarabine at
             standard lymphodepleting doses).